{"address1": "333 Lakeside Drive", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "650 574 3000", "fax": "650 578 9264", "website": "https://www.gilead.com", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.", "fullTimeEmployees": 18000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel P.  O'Day", "age": 59, "title": "Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 7267338, "exercisedValue": 0, "unexercisedValue": 9635551}, {"maxAge": 1, "name": "Mr. Andrew D. Dickinson", "age": 53, "title": "Executive VP & CFO", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 2935112, "exercisedValue": 0, "unexercisedValue": 5436829}, {"maxAge": 1, "name": "Ms. Deborah H. Telman", "age": 58, "title": "Executive VP of Corporate Affairs, General Counsel & Corporate Secretary", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 2323080, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Johanna  Mercier", "age": 52, "title": "Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 3322200, "exercisedValue": 0, "unexercisedValue": 3864125}, {"maxAge": 1, "name": "Dr. Merdad V. Parsey M.D., Ph.D.", "age": 59, "title": "Chief Medical Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 3074714, "exercisedValue": 0, "unexercisedValue": 3047349}, {"maxAge": 1, "name": "Ms. Sandra  Patterson", "age": 56, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacquie  Ross C.F.A.", "title": "Vice President of Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyoti K. Mehra", "age": 47, "title": "Executive Vice President of Human Resources", "yearBorn": 1976, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Linda Slanec Higgins Ph.D.", "age": 61, "title": "Senior Vice President of Research, Innovation & Portfolio", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rudolf  Ertl", "age": 77, "title": "Senior Vice President of Commercial Operations of Australia, Canada, Europe", "yearBorn": 1946, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 3, "shareHolderRightsRisk": 1, "overallRisk": 1, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 73.98, "open": 73.9, "dayLow": 73.03, "dayHigh": 74.28, "regularMarketPreviousClose": 73.98, "regularMarketOpen": 73.9, "regularMarketDayLow": 73.03, "regularMarketDayHigh": 74.28, "dividendRate": 3.08, "dividendYield": 0.0416, "exDividendDate": 1710374400, "payoutRatio": 0.6667, "fiveYearAvgDividendYield": 3.97, "beta": 0.2, "trailingPE": 16.242222, "forwardPE": 9.837147, "volume": 5810324, "regularMarketVolume": 5810324, "averageVolume": 7354165, "averageVolume10days": 8515070, "averageDailyVolume10Day": 8515070, "bid": 73.09, "ask": 73.12, "bidSize": 300, "askSize": 200, "marketCap": 91053326336, "fiftyTwoWeekLow": 71.37, "fiftyTwoWeekHigh": 87.87, "priceToSalesTrailing12Months": 3.357919, "fiftyDayAverage": 76.7046, "twoHundredDayAverage": 77.36675, "trailingAnnualDividendRate": 3.0, "trailingAnnualDividendYield": 0.0405515, "currency": "USD", "enterpriseValue": 109386407936, "profitMargins": 0.20892, "floatShares": 1243146032, "sharesOutstanding": 1245769984, "sharesShort": 19674265, "sharesShortPriorMonth": 15662309, "sharesShortPreviousMonthDate": 1706659200, "dateShortInterest": 1709164800, "sharesPercentSharesOut": 0.015800001, "heldPercentInsiders": 0.00102, "heldPercentInstitutions": 0.88525003, "shortRatio": 2.55, "shortPercentOfFloat": 0.0177, "impliedSharesOutstanding": 1245769984, "bookValue": 18.325, "priceToBook": 3.98854, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": -0.129, "netIncomeToCommon": 5664999936, "trailingEps": 4.5, "forwardEps": 7.43, "pegRatio": 2.04, "lastSplitFactor": "2:1", "lastSplitDate": 1359331200, "enterpriseToRevenue": 4.034, "enterpriseToEbitda": 8.754, "52WeekChange": -0.0606907, "SandP52WeekChange": 0.32311738, "lastDividendValue": 0.77, "lastDividendDate": 1710374400, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GILD", "underlyingSymbol": "GILD", "shortName": "Gilead Sciences, Inc.", "longName": "Gilead Sciences, Inc.", "firstTradeDateEpochUtc": 696090600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8659e669-8ec5-3b0f-9929-db5db506231f", "messageBoardId": "finmb_29002", "gmtOffSetMilliseconds": -14400000, "currentPrice": 73.09, "targetHighPrice": 121.0, "targetLowPrice": 69.0, "targetMeanPrice": 85.04, "targetMedianPrice": 81.0, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 25, "totalCash": 8350000128, "totalCashPerShare": 6.703, "ebitda": 12494999552, "totalDebt": 25657999360, "quickRatio": 1.153, "currentRatio": 1.426, "totalRevenue": 27115999232, "debtToEquity": 112.787, "revenuePerShare": 21.728, "returnOnAssets": 0.09779, "returnOnEquity": 0.25538, "freeCashflow": 8793249792, "operatingCashflow": 8006000128, "earningsGrowth": -0.131, "revenueGrowth": -0.037, "grossMargins": 0.77803004, "ebitdaMargins": 0.46080002, "operatingMargins": 0.42213002, "financialCurrency": "USD", "trailingPegRatio": 0.4576}